References
1 - Fathi AT, DiNardo CD, Kline I, et al. Differentiation Syndrome
Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate
Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA Oncol. 2018 Aug 1;
4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695. PMID: 29346478; PMCID:
PMC5885269.
2 - DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with
Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med.
2018 Jun 21; 378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018
Jun 2. PMID: 29860938.